Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652534 | 0.96 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20154157 | 0.91 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8886541 | 0.91 | LOXL2 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL334559 | 0.89 | SLC7A5 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28864843 | 0.89 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3602876 | 0.89 | NOTUM (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1096840 | 0.87 | CA1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31568418 | 0.87 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29508489 | 0.87 | ALDH1A1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1401435 | 0.87 | CA12 (0.44) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404236-B2 | Non-peptidic cell-penetrating motifs | OHIO STATE INNOVATION FOUNDATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025082283-A1 | LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| WO-2024199069-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240101509-A1 | NON-PEPTIDIC CELL-PENETRATING MOTIFS | OHIO STATE INNOVATION FOUNDATION | 2024-03-28 | — | — | US | disclosed |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-11814341-B2 | Non-peptidic cell-penetrating motifs | OHIO STATE INNOVATION FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814341-B2 | Non-peptidic cell-penetrating motifs | OHIO STATE INNOVATION FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-1995020590-A1 | ENANTIOSELECTIVE RECEPTORS FOR AMINO ACID DERIVATIVES, AND OTHER COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1995-08-03 | — | — | WO | disclosed |
| US-5412148-A | Amplifier molecules derived from diethylene triaminepentaacetic acid for enhancement of diagnosis and therapy | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0296749-B1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LTD (GB) | 1994-10-26 | — | — | EP | disclosed |
| US-5342934-A | For resolution, purification | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1994003593-A1 | AMPLIFIER MOLECULES FOR ENHANCEMENT OF DIAGNOSIS AND THERAPY | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1994000455-A1 | ENANTIOSELECTIVE RECEPTOR FOR AMINO ACID DERIVATIVES, AND OTHER COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5252317-A | Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1993-10-12 | — | — | US | disclosed |
| US-5135737-A | Amplifier molecules for enhancement of diagnosis and therapy | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1992-08-04 | — | — | US | disclosed |
| US-4935437-A | (Substituted aralkyl) heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-19 | — | — | US | disclosed |
| EP-0296749-A1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LIMITED (GB) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404236-B2 | Non-peptidic cell-penetrating motifs | TIMM50, TIMM10, PITRM1 | CA12 4061/4885CA1 4323/4885CA2 4103/4885 |
| US-20240101509-A1 | NON-PEPTIDIC CELL-PENETRATING MOTIFS | TIMM50, TIMM10, PITRM1 | CA12 4061/4885CA1 4323/4885CA2 4103/4885 |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | CA12 4345/4885CA1 2710/4885CA2 4152/4885 |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | CA12 403/4885CA1 1665/4885CA2 1853/4885 |
| US-11814341-B2 | Non-peptidic cell-penetrating motifs | TIMM50, TIMM10, PITRM1 | CA12 4061/4885CA1 4323/4885CA2 4103/4885 |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | CA12 403/4885CA1 1665/4885CA2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.